Max Healthcare Institute Limited
Max Healthcare Institute Limited provides medical and healthcare services in India. It offers services in various specialties, including cardiac sciences, orthopedics, oncology, renal sciences, neurosciences, minimal access and general surgery, pulmonology, obstetrics, gynecology, pediatrics, and nephrology, liver and biliary sciences, gastroenterology and Gi surgery, plastic and reconstructive surgery, and organ transplants, as well as ear, nose, and throat. The company also provides Max@Home, a platform that offers health and wellness services at home; and MaxLab, which provides diagnostic services to patients outside its network of hospitals through various channels comprising third-party hospital laboratory management. It operates through a network of healthcare facilities, including hospitals and medical centres. The company was incorporated in 2001 and is based in Gurugram, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 108.8%
Concerns1
- Low return on equity of 8.9%
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ2.66 K Cr | β | βΉ701.00 Cr | β | β | 8.5% | 13.8% | 2.0% |
| Mar 2024 | βΉ2.34 K Cr | β | βΉ687.00 Cr | β | β | 8.9% | 22.9% | -1.0% |
| Mar 2023 | βΉ1.91 K Cr | β | βΉ694.00 Cr | β | β | 9.9% | 7.3% | 109.0% |
| Mar 2022 | βΉ1.77 K Cr | β | βΉ332.00 Cr | β | β | 5.3% | 72.2% | -302.4% |
| Mar 2021 | βΉ1.03 K Cr | β | βΉ-164.00 | β | β | -2.8% | 1647.5% | 5366.7% |
| Mar 2020 | βΉ59.00 Cr | β | βΉ-3.00 | β | β | -0.1% | -94.1% | -87.0% |
| Mar 2019 | βΉ1.01 K Cr | β | βΉ-23.00 | β | β | -1.8% | -4.8% | -17.9% |
| Mar 2018 | βΉ1.06 K Cr | β | βΉ-28.00 | β | β | -2.1% | 7.6% | 115.4% |
| Mar 2017 | βΉ984.00 Cr | β | βΉ-13.00 | β | β | -1.0% | 7.9% | -45.8% |
| Mar 2016 | βΉ912.00 Cr | β | βΉ-24.00 | β | β | -1.9% | 15.4% | -36.8% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 2,787 |
| Total Expenses | 1,975 |
| EBIT / Operating Profit | 812 |
| OPM % | 29% |
| Other Income | 244 |
| Finance Costs | 51 |
| Depreciation & Amortisation | 141 |
| Profit Before Tax | 864 |
| Tax % | - |
| Net Profit / PAT | 642 |
| EPS (βΉ) | 6.60 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Max Healthcare Institute Limitedthis co. | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Lupin Ltd | βΉ99.47 K Cr | βΉ16.97 K Cr | 18.60 | 3.66 | 27.43 | 15.7% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |